Cargando…

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Due to the CD1d restricted recognition of altered glycolipids, Vα24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-the shelf-therapeutics across Human Leukocyte Antigen (HLA) bar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poels, Renée, Drent, Esther, Lameris, Roeland, Katsarou, Afroditi, Themeli, Maria, van der Vliet, Hans J., de Gruijl, Tanja D., van de Donk, Niels W. C. J., Mutis, Tuna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865760/ https://www.ncbi.nlm.nih.gov/pubmed/33499253 http://dx.doi.org/10.3390/ijms22031096

Ejemplares similares

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Invariant Natural Killer T and Mucosal-Associated Invariant T Cells in Asthmatic Patients
por: Lezmi, Guillaume, et al.
Publicado: (2018)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)

Immunometabolic Activation of Invariant Natural Killer T Cells
por: Ververs, Francesca A., et al.
Publicado: (2018)

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity
por: Van Kaer, Luc, et al.
Publicado: (2018)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
por: Veluchamy, John P., et al.
Publicado: (2017)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
por: Kang, Liqing, et al.
Publicado: (2020)

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
por: Du, Zhicheng, et al.
Publicado: (2023)

Antitumor Responses of Invariant Natural Killer T Cells
por: Altman, Jennie B., et al.
Publicado: (2015)

Antigen specificity of invariant natural killer T-cells
por: Birkholz, Alysia M., et al.
Publicado: (2015)

The two faces of invariant natural killer T cells
por: Walton, Emma L.
Publicado: (2015)

Metabolism in Invariant Natural Killer T Cells: An Overview
por: Yarosz, Emily L., et al.
Publicado: (2021)

Invariant natural killer T cells in lung diseases
por: Jeong, Dongjin, et al.
Publicado: (2023)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_068ljkrj8r5g9smvpd6n15dg11